Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting

@article{Howell2009PharmacokineticsOA,
  title={Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting},
  author={J. Howell and J. Smeets and H. Drenth and David Gill},
  journal={Journal of Oncology Pharmacy Practice},
  year={2009},
  volume={15},
  pages={223 - 231}
}
Objective. To determine the pharmacokinetic (PK) profile of granisetron transdermal formulation and examine its possible relationship with age, gender, and renal function. Methods. This article describes a Phase I PK study and a post hoc pooled population PK analysis. The Phase I study was a randomized, cross-over study that assessed PK parameters of three granisetron patch sizes and oral granisetron. The pooled population PK analysis included data from three trials in healthy subjects (n = 48… Expand
Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review
  • A. Tuca
  • Medicine
  • Cancer management and research
  • 2009
TLDR
Clinical trials show that transdermal granisetron is effective and safe in controlling acute emesis induced by chemotherapy with both moderate and high emetogenic potential. Expand
Granisetron Transdermal System in the Management of Chemotherapy-Induced Nausea and Vomiting
TLDR
Transdermal granisetron showed noninferiority to other formulations of serotonin-type 3 receptor antagonists for highly and moderately emetogenic – including multiday – chemotherapy, and the adverse effects were not significantly different from other formulations. Expand
Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study.
TLDR
GTDS provided effective and well-tolerated control of CINV in Chinese patients, especially to non-cisplatin-contained regimen and female, and both treatments were well tolerated and safe. Expand
Granisetron: a review of pharmacokinetics and clinical experience in chemotherapy induced - nausea and vomiting
TLDR
According to current literature, granisetron 2 mg orally or 0,01mg/kg (1 mg) intravenously per day, co-administered with dexamethasone and NK-1 antagonists is the recommended regime for highly emetogenic chemotherapy. Expand
Results from four pharmacokinetic studies of the granisetron transdermal system
TLDR
Findings from these four studies suggest that no GTDS dose adjustments are needed for patient age, body mass index, or tricep skinfold thickness, and should external heat be applied to the GTDS short-tem, there are unlikely to be significant adverse consequences. Expand
A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients
TLDR
The GTS offers a convenient alternative option for relieving CINV in patients receiving MEC and was well tolerated and safe, and the safety, tolerability, and FLI-E scores of the GTS were comparable to those of control group. Expand
Transdermal Granisetron
TLDR
Transdermal granisetron was generally well tolerated in clinical trials, with few adverse events being treatment related. Expand
Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study
TLDR
The GTDS provides effective, well-tolerated control of CINV associated with moderately or highly emetogenic multi-day chemotherapy and offers a convenient alternative route for delivering granisetron for up to 7 days that is as effective as oral granisettron. Expand
Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study
TLDR
Transdermal granisetron is a good alternative therapeutic option to palonosetron for preventing CINV after MEC and both treatments were well tolerated and safe. Expand
Pharmacokinetics and Repolarization Effects of Intravenous and Transdermal Granisetron
TLDR
GTDS was not associated with statistically or clinically significant effects on QTcF or other electrocardiographic variables, and provides useful clarification on the effect of granisetron delivered by GTDS on cardiac repolarization. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 12 REFERENCES
Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
PURPOSE To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a singleExpand
Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group.
The efficacy and safety of three different doses of granisetron (2 micrograms kg-1, group A; 10 micrograms kg-1, group B; 40 micrograms kg-1, group C) were compared in a randomised, double-blindExpand
Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group.
The efficacy and safety of three different doses of granisetron (2 micrograms kg-1, group A; 10 micrograms kg-1, group B; 40 micrograms kg-1, group C) were compared in a randomised, double-blindExpand
Granisetron: an update on its clinical use in the management of nausea and vomiting.
Nausea and vomiting are typical side effects of cytotoxic therapy and some surgical procedures. These symptoms can represent a major therapeutic challenge and, if inadequately controlled byExpand
The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: a randomized crossover trial.
1. We report a single-blind randomized crossover trial comparing the efficacy of tropisetron plus dexamethasone (TROPDEX) vs conventional combination of metoclopramide, dexamethasone andExpand
Use of Transdermal Drug Formulations in the Elderly
Transdermal drug delivery systems are pharmaceutical forms designed to administer a drug through the skin to obtain a systemic effect. They ensure a constant rate of drug administration and aExpand
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
  • M. Kris, P. Hesketh, +8 authors S. Grunberg
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
PURPOSE To update the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology. UPDATE METHODOLOGY The Update Committee completed a review and analysis of data publishedExpand
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference.
BACKGROUND In the late 1990s, several professional organizations convened antiemetic guideline groups and published the findings of these expert panels. Each of these documents was based on analysesExpand
Passive transdermal drug delivery systems
The skin has evolved as a formidable barrier against invasion by external microorganisms and against the prevention of water loss. Notwithstanding this, transdermal drug delivery systems have beenExpand
Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting.
Chemotherapy-induced nausea and vomiting (CINV) continues to have a considerable effect on the physical and psychological well-being of patients with cancer, despite significant advances inExpand
...
1
2
...